Skip to main content
. 2019 Aug 6;143(4):243–254. doi: 10.1159/000502012

Fig. 2.

Fig. 2

Serum ferritin concentrations during treatment with ­molidustat or placebo/active comparator: (a) DIALOGUE 1, (b) DIALOGUE 2, and (c) DIALOGUE 4. Non-iron users are patients who did not receive iron supplementation during the study. EoT, end of treatment.